Evidence of aminoglycoside cochleotoxicity measured by standard & high frequency audiometry and Distortion-Product otoacoustic emissions in paediatric Cystic Fibrosis patients  by Al-Malky, G. et al.
S48 5. Microbiology
191 Monitoring of Tobramycin Levels by Fingerprick Sampling
A.M. Jones1, B. Keevil2, J. Beisty1, A.K. Webb1, D. McKenna1, D. Clough1.
1Manchester Adult CF Centre, Wythenshawe Hospital, Manchester, United
Kingdom; 2Biochemistry, Wythenshawe Hospital, Manchester, United Kingdom
Introduction: Tobramycin, an aminoglycoside antibiotic, is widely used against
Gram negative bacterial infections and is particularly useful for the treatment of
P. aeruginosa in patients with cystic ﬁbrosis. It has a narrow therapeutic range
and monitoring of the drug is required to reduce serious side effects such as
nephrotoxicity and ototoxicity. Dosage alterations based on the results of drug
monitoring have been found to improve efﬁcacy and minimise toxicity. Monitoring
currently requires venesection, but patients may ﬁnd ﬁngerprick samples less painful
and more acceptable.
Methods: Venous and ﬁnger prick blood samples were collected from 45 pa-
tients attending the Manchester Adult Cystic Fibrosis Centre who were receiving
intravenous tobramycin therapy. Tobramycin concentrations were measured on a
Cobas Integra analyser using ﬂuorescence polarization (Roche Diagnostics, Lewes,
UK) according to the manufacturers instructions. The assay requires 3 uL sample
although a dead volume of approximately 100 uL is required in the sample cup.
The range of the assay is from 0.04 to 10mg/L.
Results: Bland Altman analysis showed good agreement between the two different
collection methods with a bias of 0.14mg/L, 95% limits of agreement −0.81 to
0.53. Passing and Bablock analysis showed ﬁngerprick tobramycin = 0.94 venous
tobramycin +0.02.
Conclusion: Tobramycin results from ﬁngerprick sampling are interchangeable with
those from venous sampling. Many patients receiving a course of intravenous to-
bramycin may prefer ﬁngerprick sampling as a more acceptable means of obtaining
specimens for analysis.
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Despite the known ototoxic effect of aminoglycoside (AG) antibiotics, regular
surveillance of hearing is not routinely undertaken in cystic ﬁbrosis (CF) patients
in the UK. Many patients can be exposed to very high cumulative doses of AGs
in the management of pulmonary exacerbations. Furthermore, in the paediatric CF
population there has been wide variability in the reported prevalence of ototoxicity,
ranging from 0 to 6%
In this study, 43 CF patients, with varying degrees of exposure to AGs (Amikacin,
Tobramycin and Gentamicin), from the paediatric CF unit at Great Ormond Street
hospital were assessed. 37/43 had previously received AGs. Of these 37, 24 had
received regular repeated IV AGs, on average, every 3 months (high exposure
group). 6/37 (16%) had cochleotoxicity, all of whom were of the high exposure
patients. This was evident through a signiﬁcant (p< 0.05) elevation in thresholds
measured through standard and high frequency audiometry at frequencies 8kHz and
above and through a drop in distortion-product otoacoustic emissions (DPOAEs)
amplitudes at f2 frequencies of 2002–6348 Hz. The remaining 31/37 (84%) had
normal, even exceptionally good hearing up to frequencies 20 kHz.
In summary, a signiﬁcant number of CF patients who have regular IV AG course
were found to have high frequency hearing loss at  8kHz. The majority of CF
patients had completely normal hearing. We would therefore recommend regular
hearing tests on children with CF who receive IV AG.
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Background: Aminoglycosides are highly active against Pseudomonas aeruginosa
but are known to be nephro- and ototoxic. With increasing CF life expectancy, the
frequency of aminoglycoside exposure is increasing with possible increased risk of
ototoxic side effects. There is no recent data describing the prevalence of ototoxicity
in CF populations.
Aims: 1. To examine whether ototoxicity is a clinical problem in patients attending
a large regional adult Cf centre. To examine the association of ototoxicity with
intravenous aminoglycosides, nebulised TOBI®, and the m.1555A>G mutation, (a
mitochondrial mutation implicated in the development of aminoglycoside induced
ototoxicity).
Methods:We conducted a retrospective audit of audiograms performed in MACFC
patients over eleven years. All were reviewed by a consultant ENT surgeon.
Results were compared to normal subjects from the National Study of Hearing
and correlated against intravenous aminoglycoside and TOBI exposure. Results of
the m.1555A>G screening test were collected.
Results: 51 patient audiograms were identiﬁed and examined. 17 (33.3%) were
clinically abnormal and analysis demonstrated that CF patient audiometry was
signiﬁcantly worse than that of normal subjects. There was a statistically signiﬁcant
positive relationship between intravenous aminoglycoside exposure and hearing loss
at all frequencies (2kHz: r = 0.609, p< 0.001; 4kHz: r = 0.572, p< 0.001; 8kHz:
r = 0.549, p< 0.001). No relationship with nebulised TOBI® was identiﬁed. 1 patient
tested positive for the m.1555A>G mutation.
Discussion: Hearing loss is a signiﬁcant problem for patients attending the MACFC.
Intravenous aminoglycoside exposure is strongly implicated. A large prospective
study is required.
194 Investigation into the potential of sub-lethal photodynamic
antimicrobial chemotherapy (PACT) to reduce susceptibility of
Pseudomonas aeruginosa to antibiotics
C.M. Cassidy1, J.S. Elborn1, R.F. Donnelly1, M.M. Tunney1. 1Queen’s University
Belfast, Belfast, United Kingdom
Introduction and Aims: We have previously shown that PACT can be used to
achieve >99% kill of CF-isolated P. aeruginosa. The aim of this study was to
determine if exposure of clinical P. aeruginosa isolates to sub-lethal doses of PACT
could result in decreased susceptibility to previously lethal PACT and a range of
antibiotics.
Method: Planktonic cultures of bacteria were exposed to sub-lethal Methylene
blue (MB) and meso-tetra (N-methyl-4-pyridyl) porphine tetra tosylate (TMP)-
mediated PACT over a 72 hour period. Sensitivity of surviving organisms to a
range of antibiotics was then determined using E-test® strips and compared with the
sensitivity of an untreated control. Surviving bacteria were treated with previously
lethal photosensitizer-light combinations.
Results: Exposure to sub-lethal PACT resulted in no signiﬁcant decreases in
susceptibility to previously lethal PACT. E-test® results for P. aeruginosa strain
PAO1 revealed that exposure to sub-lethal photosensitizer concentrations caused a
decreased susceptibility to meropenem, whilst exposure to TMP-PACT decreased
susceptibility to ceftazidine. Susceptibility to tobramycin and piperacillin was
unaltered. In all cases, reduction in minimum inhibitory concentration (MIC) was
not greater than one doubling dilution of antibiotic.
Conclusion: Sub-lethal PACT exposure does not affect the susceptibility of
P. aeruginosa to previously lethal PACT or to the range of antibiotics tested. Any
changes in MIC were not signiﬁcant, as they did not cross breakpoints between
resistant and susceptible for any organism or antibiotic tested. Thus, PACT remains
a potential treatment option in P. aeruginosa mediated pulmonary infection.
